MediaPharma

Executive Summary

MediaPharma is an Italian drug discovery company specializing in antibody-drug conjugates (ADCs) for oncology and other severe diseases with unmet medical needs. Founded in 2001 and headquartered in Milan, the company leverages leading-edge technologies to develop innovative monoclonal antibodies. Currently at an advanced preclinical stage, MediaPharma has a robust pipeline of ADC candidates targeting various cancers. The company's focus on ADCs positions it within a rapidly growing sector of the biopharmaceutical industry, where several ADC therapies have achieved commercial success. Despite being privately held with limited financial disclosure, MediaPharma's long-standing expertise and strong scientific foundation suggest potential for future growth. The company's ability to advance its lead candidates into clinical trials and secure partnerships will be critical for value creation.

Upcoming Catalysts (preview)

• Q2 2026IND Filing for Lead ADC Candidate70% success
• H2 2026Partnership or Licensing Deal50% success
• Q4 2026First-in-Human Trial Initiation60% success